Cas:74696-96-1 3-acetyl-7-diethylamino-chromen-2-one manufacturer & supplier

We serve Chemical Name:3-acetyl-7-diethylamino-chromen-2-one CAS:74696-96-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

3-acetyl-7-diethylamino-chromen-2-one

Chemical Name:3-acetyl-7-diethylamino-chromen-2-one
CAS.NO:74696-96-1
Synonyms:7-diethylamino-3-acetylchromen-2-one;2H-1-Benzopyran-2-one, 3-acetyl-7-(diethylamino)-;3-acetyl-7-diethylaminocoumarin;3-acetyl-7-diethylamino-chromen-2-one;3-acetyl-7-diethylamino-2H-chromen-2-one;3-Acetyl-7-(diethylamino)-2H-chromen-2-one
Molecular Formula:C15H17NO3
Molecular Weight:259.300
HS Code:2932209090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:463.1±45.0 °C at 760 mmHg
Density:1.2±0.1 g/cm3
Index of Refraction:1.582
PSA:50.52000
Exact Mass:259.120850
LogP:3.10

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 7-diethylamino-3-acetylchromen-2-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Acetyl-7-(diethylamino)-2H-chromen-2-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,7-diethylamino-3-acetylchromen-2-one Use and application,2H-1-Benzopyran-2-one, 3-acetyl-7-(diethylamino)- technical grade,usp/ep/jp grade.


Related News: As further tools are created to improve biocatalyst development, these can likewise be assessed for their capacity to add value to a project. trypsinogen manufacturers As part of the strategy, the government will review the research funding offer to retain, attract and support the very best researchers, innovators and their teams. 4-chloro-2-[[dideuterio-(3,4,5-trideuteriofuran-2-yl)methyl]amino]-5-sulfamoylbenzoic acid suppliers “This announcement reflects another important regulatory milestone in the development of this medicine,” said Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. 2-[4,5-bis(dimethylcarbamoyl)-1,3,2-dioxaborolan-2-yl]-4-N,4-N,5-N,5-N-tetramethyl-1,3,2-dioxaborolane-4,5-dicarboxamide vendor & factory.